Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT)

被引:42
作者
Barnholtz-Sloan, JS
Morris, R
Malone, JM
Munkarah, AR
机构
[1] Wayne State Univ, Sch Med, Dept Internal Med, Div Hematol Oncol, Detroit, MI 48201 USA
[2] Karmanos Canc Inst, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Detroit, MI 48201 USA
关键词
ovarian cancer; survival; malignant mixed mullerian; epithelial;
D O I
10.1016/j.ygyno.2004.02.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To analyze the survival of women with malignant, mixed mullerian tumors of the ovary (OMMMT) compared to women with epithelial ovarian cancer (EOC). Methods. Data from the Surveillance, Epidemiology and End Results (SEER) Program on 14 025 women diagnosed with primary invasive ovarian cancer between 1988 and 1997 were used for this analysis (382 had OMMMT). Differences in distribution of prognostic variables by histological type were compared using a chi-square test. Multivariable survival models were fit using Cox proportional hazards regression analysis to compare risk of death for OMMMT compared to EOC. Analyses were also performed using cases with OMMMT compared to high-grade EOC only. Results. Women with OMMMT were older at diagnosis and were more likely to have primary surgery compared to women with EOC. The majority of women in either histological group had advanced-stage disease at diagnosis. Women with OMMMT had a significant increased risk of death from any cause whether being compared to all women with EOC (HR 1.69, 95% CI = 1.50,1.90) or to women with high-grade EOC only (HR = 1.58, 95% CI = 1.40,1.79). Women with advanced-stage OMMMT were at a 60% increased risk of death compared to women with advanced-stage, high-grade EOC, after adjustment for other variables of interest (adjusted HR 1.60, 95% CI = 1.40,1.84). There was no difference in risk of death for these two groups of women with early-stage disease. Conclusion. OMMMT is a rare malignancy compared to EOC and had a significantly worse prognosis compared to EOC, (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:506 / 512
页数:7
相关论文
共 37 条
[1]  
*AM CANC SOC, 2004, CANC FACTS FIG 2003
[2]   PLATINUM-BASED COMBINATION CHEMOTHERAPY FOR MALIGNANT MIXED MESODERMAL TUMORS OF THE OVARY [J].
ANDERSEN, WA ;
YOUNG, DE ;
PETERS, WA ;
SMITH, EB ;
BAGLEY, CM ;
TAYLOR, PT .
GYNECOLOGIC ONCOLOGY, 1989, 32 (03) :319-322
[3]  
[Anonymous], J R STAT SOC
[4]  
AVERETTE HE, 1993, CANCER, V71, P1629
[5]  
AVERETTE HE, 1995, CANCER, V76, P1096, DOI 10.1002/1097-0142(19950915)76:6<1096::AID-CNCR2820760626>3.0.CO
[6]  
2-4
[7]  
BARAKAT RR, 1992, OBSTET GYNECOL, V80, P660
[8]   Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades [J].
Barnholtz-Sloan, JS ;
Schwartz, AG ;
Qureshi, F ;
Jacques, S ;
Malone, J ;
Munkarah, AR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (04) :1120-1127
[9]   Ethnic differences in survival among women with ovarian carcinoma [J].
Barnholtz-Sloan, JS ;
Tainsky, MA ;
Abrams, J ;
Severson, RK ;
Qureshi, F ;
Jacques, SM ;
Levin, N ;
Schwartz, AG .
CANCER, 2002, 94 (06) :1886-1893
[10]   OVARIAN MALIGNANT MIXED MULLERIAN TUMORS TREATED WITH PLATINUM-BASED CHEMOTHERAPY [J].
BICHER, A ;
LEVENBACK, C ;
SILVA, EG ;
BURKE, TW ;
MORRIS, M ;
GERSHENSON, DM .
OBSTETRICS AND GYNECOLOGY, 1995, 85 (05) :735-739